ARROWHEAD PHARMACEUTICALS (ARWR) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$62.75
+3.3% on the day
+74.0% over 12 months
52-week range $35.41 – $89.59
Share price and insider trades
ARWR closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$37.3M
Insiders buying0
Insiders selling10
ARROWHEAD PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $37.3M of ARWR stock on the open market.
Get emailed when insiders cluster-buy stocks like ARWR
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ARWR insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $1.2M | 2 |
| Q2 2026 | — | 0 | $1.9M | 5 |
| Q1 2026 | — | 0 | $7.2M | 22 |
| Q4 2025 | — | 0 | $27.8M | 36 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 ARROWHEAD PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $37.3M. Among insiders with enough purchase history to measure, Hongbo Lu (Director) has the highest Insider Score at 24. 45 of 65 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ARWR earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 4, 2026 | +15.8% | None | +1.0%S&P +1.6% | -0.7% |
| May 7, 2026 | +11.4% | Sold $1.7M | -8.2%S&P +0.5% | +0.6% |
| Feb 5, 2026 | +4.3% | None | -5.2%S&P +0.6% | -7.3% |
| Nov 25, 2025 | +12.8% | None | +30.4%S&P +1.6% | +21.6% |
| Aug 7, 2025 | +9.0% | None | +0.7%S&P +0.7% | +77.1% |
| May 12, 2025 | -2.3% | None | +17.3%S&P +4.0% | +6.2% |
| Feb 10, 2025 | -6.0% | None | -6.7%S&P +0.8% | -20.2% |
| Nov 26, 2024 | -14.2% | None | +39.2%S&P +0.2% | -27.5% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 20SEC | Michael S PerryDirector | Sell | 11,600111,459 held (−9%) | $87.30 | $1.0M | -28.1% | — |
| Aug 20SEC | Adeoye Y OlukotunDirector | Sell | 2,00031,600 held (−6%) | $86.96 | $174K | -27.8% | — |
| May 14SEC | Hongbo LuDirector | Sell Plan | 2,97052,012 held (−5%) | $76.88 | $228K | -18.4% | 24 |
| Apr 24SEC | James C HamiltonChief Medical Officer | Sell Plan | 10,000226,958 held (−4%) | $75.00 | $750K | -16.3% | — |
| Apr 24SEC | Daniel Joseph ApelCFO | Sell Plan | 8,730162,905 held (−5%) | $71.92 | $628K | -12.8% | — |
| Apr 24SEC | Daniel Joseph ApelCFO | Sell Plan | 3,208172,792 held (−2%) | $70.11 | $225K | -10.5% | — |
| Apr 24SEC | Daniel Joseph ApelCFO | Sell Plan | 1,157171,635 held (−1%) | $70.45 | $82K | -10.9% | — |
| Mar 9SEC | James C HamiltonChief Medical Officer | Sell Plan | 10,000236,958 held (−4%) | $64.19 | $642K | -2.2% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 14,792186,615 held (−7%) | $63.01 | $932K | -0.4% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 13,451500,418 held (−3%) | $62.96 | $847K | -0.3% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 12,711173,904 held (−7%) | $63.95 | $813K | -1.9% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 11,842488,576 held (−2%) | $63.84 | $756K | -1.7% | — |
| Jan 5SEC | Christopher Richard AnzaloneCEO | Sell Plan | 7,4163,798,510 held (−0%) | $65.88 | $489K | -4.8% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 6,164513,869 held (−1%) | $62.23 | $384K | +0.8% | — |
| Jan 5SEC | Christopher Richard AnzaloneCEO | Sell Plan | 5,7713,792,739 held (−0%) | $66.39 | $383K | -5.5% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 6,090201,407 held (−3%) | $62.28 | $379K | +0.8% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 5,873477,290 held (−1%) | $62.91 | $369K | -0.3% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 4,625207,497 held (−2%) | $61.24 | $283K | +2.5% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 4,368520,033 held (−1%) | $61.20 | $267K | +2.5% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 2,700485,876 held (−1%) | $64.44 | $174K | -2.6% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 2,336474,954 held (−0%) | $64.04 | $150K | -2.0% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 1,200172,704 held (−1%) | $64.49 | $77K | -2.7% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 900484,976 held (−0%) | $66.01 | $59K | -4.9% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 900483,163 held (−0%) | $62.25 | $56K | +0.8% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 600484,063 held (−0%) | $61.12 | $37K | +2.7% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 437172,267 held (−0%) | $65.97 | $29K | -4.9% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 313484,663 held (−0%) | $68.00 | $21K | -7.7% | — |
| Jan 5SEC | James C HamiltonChief Medical Officer | Sell Plan | 309171,958 held (−0%) | $68.00 | $21K | -7.7% | — |
| Jan 5SEC | Patrick O'brienCOO | Sell Plan | 46474,908 held (−0%) | $68.00 | $3K | -7.7% | — |
| Dec 30SEC | Christopher Richard AnzaloneCEO | Sell Plan | 35,1813,822,471 held (−1%) | $69.33 | $2.4M | -9.5% | — |
| Dec 30SEC | Christopher Richard AnzaloneCEO | Sell Plan | 16,5453,805,926 held (−0%) | $68.69 | $1.1M | -8.6% | — |
| Dec 30SEC | Mauro FerrariDirector | Sell Plan | 7,53069,053 held (−10%) | $70.00 | $527K | -10.4% | — |
| Dec 23SEC | Christopher Richard AnzaloneCEO | Sell Plan | 10,0123,808,500 held (−0%) | $68.33 | $684K | -8.2% | — |
| Dec 23SEC | Christopher Richard AnzaloneCEO | Sell Plan | 8,1473,819,831 held (−0%) | $68.01 | $554K | -7.7% | — |
| Dec 23SEC | Adeoye Y OlukotunDirector | Sell Plan | 6,08334,427 held (−15%) | $68.04 | $414K | -7.8% | — |
| Dec 23SEC | William D. WaddillDirector | Sell Plan | 5,45157,063 held (−9%) | $68.01 | $371K | -7.7% | — |
| Dec 23SEC | Victoria VakienerDirector | Sell Plan | 5,28137,683 held (−12%) | $67.97 | $359K | -7.7% | — |
| Dec 23SEC | Christopher Richard AnzaloneCEO | Sell Plan | 3,9793,827,978 held (−0%) | $66.67 | $265K | -5.9% | — |
| Dec 23SEC | Adeoye Y OlukotunDirector | Sell Plan | 3,09040,510 held (−7%) | $66.70 | $206K | -5.9% | — |
| Dec 23SEC | Victoria VakienerDirector | Sell Plan | 2,79942,964 held (−6%) | $66.63 | $186K | -5.8% | — |
| Dec 23SEC | Christopher Richard AnzaloneCEO | Sell Plan | 2,5743,805,926 held (−0%) | $68.85 | $177K | -8.9% | — |
| Dec 23SEC | William D. WaddillDirector | Sell Plan | 2,41662,514 held (−4%) | $66.66 | $161K | -5.9% | — |
| Dec 23SEC | Victoria VakienerDirector | Sell Plan | 1,96035,723 held (−5%) | $68.39 | $134K | -8.2% | — |
| Dec 23SEC | Christopher Richard AnzaloneCEO | Sell Plan | 1,3193,818,512 held (−0%) | $68.48 | $90K | -8.4% | — |
| Dec 23SEC | Adeoye Y OlukotunDirector | Sell Plan | 82733,600 held (−2%) | $68.48 | $57K | -8.4% | — |
| Dec 23SEC | William D. WaddillDirector | Sell Plan | 50056,563 held (−1%) | $68.53 | $34K | -8.4% | — |
| Dec 19SEC | Christopher Richard AnzaloneCEO | Sell | 46,2873,870,670 held (−1%) | $63.55 | $2.9M | -1.3% | — |
| Dec 19SEC | Christopher Richard AnzaloneCEO | Sell | 35,7503,834,920 held (−1%) | $64.51 | $2.3M | -2.7% | — |
| Dec 19SEC | Christopher Richard AnzaloneCEO | Sell | 1,9813,831,957 held (−0%) | $66.30 | $131K | -5.4% | — |
| Dec 19SEC | Christopher Richard AnzaloneCEO | Sell | 9823,833,938 held (−0%) | $65.53 | $64K | -4.2% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 100,5324,000,723 held (−2%) | $68.67 | $6.9M | -8.6% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 21,3213,979,402 held (−1%) | $69.28 | $1.5M | -9.4% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 14,0953,937,781 held (−0%) | $62.12 | $876K | +1.0% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 10,9633,951,876 held (−0%) | $61.25 | $671K | +2.4% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 8,1473,971,255 held (−0%) | $69.96 | $570K | -10.3% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 8,4763,929,305 held (−0%) | $62.94 | $533K | -0.3% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 8,4163,962,839 held (−0%) | $60.51 | $509K | +3.7% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 6,6613,922,644 held (−0%) | $64.29 | $428K | -2.4% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 3,2213,916,957 held (−0%) | $67.87 | $219K | -7.5% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 1,3003,920,344 held (−0%) | $65.77 | $86K | -4.6% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 1,0003,921,644 held (−0%) | $64.96 | $65K | -3.4% | — |
| Dec 16SEC | Christopher Richard AnzaloneCEO | Sell | 1663,920,178 held (−0%) | $66.77 | $11K | -6.0% | — |
| Dec 9SEC | Michael S PerryDirector | Sell | 16,250115,240 held (−12%) | $61.03 | $992K | +2.8% | — |
| Dec 1SEC | Mauro FerrariDirector | Sell | 8,75068,764 held (−11%) | $56.39 | $493K | +11.3% | — |
| Oct 3SEC | James C HamiltonChief Medical Officer | Sell Plan | 20,000212,122 held (−9%) | $35.00 | $700K | +79.3% | — |
Insiders at ARROWHEAD PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Christopher Richard AnzaloneCEO | — | $24.0M | Jan 5, 2026 | — |
| James C HamiltonChief Medical Officer | — | $4.6M | Apr 24, 2026 | — |
| Patrick O'brienCOO | — | $3.1M | Jan 5, 2026 | — |
| Michael S PerryDirector | — | $2.0M | Aug 20, 2026 | — |
| Mauro FerrariDirector | — | $1.0M | Dec 30, 2025 | — |
| Daniel Joseph ApelCFO | — | $934K | Apr 24, 2026 | — |
| Adeoye Y OlukotunDirector | — | $851K | Aug 20, 2026 | — |
| Victoria VakienerDirector | — | $679K | Dec 23, 2025 | — |
| William D. WaddillDirector | — | $566K | Dec 23, 2025 | — |
| Hongbo LuDirector | — | $228K | May 14, 2026 | 24 |
ARWR stock: common questions
Are ARROWHEAD PHARMACEUTICALS, INC. insiders buying ARWR stock?
In the past 12 months, 0 insiders reported open-market purchases of ARWR worth $0.
Are ARROWHEAD PHARMACEUTICALS, INC. insiders selling ARWR stock?
10 insiders reported sales worth $37.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ARWR's 52-week range?
Over the past year ARWR has traded between $35.41 and $89.59. It last closed at $62.75 on Oct 9, 2026.